Phase 4
Completed N=54
Ketamine vs Hydromorphone
Laparoscopic Gastric Bypass · Obesity · Pain, Postoperative
Source: ClinicalTrials.gov NCT03001843 ↗
Enrolled (actual)
54
Serious AEs
0.0%
Results posted
Mar 2021
Primary outcomePrimary: Pain Measured Based on Pain Medication Used on a Scale of 0-10 — 1.3; 0.7 units on a scale
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
This study will help to determine if investigators can minimize narcotic use in laparoscopic gastric bypass patients while maintaining adequate pain control. This will allow investigators to minimize the negative side effects of narcotics which is a goal in this population.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Pain Measured Based on Pain Medication Used on a Scale of 0-10 |
1.3; 0.7 | — |
| SECONDARY Length of Stay (Hours) |
43.6; 39.8 | — |
Eligibility Criteria
Inclusion Criteria
- Obese patient presenting for laparoscopic gastric bypass between 18 and 65 years of age
Exclusion Criteria
- Hypersensitivity, allergy, or contraindications to fentanyl, propofol, or ketamine.
Data sourced from ClinicalTrials.gov (NCT03001843). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.